Despite the increased use of modern contraception globally over the past 50 years, approximately 48% of all pregnancies are unintended and more than 218 million women in low- and middle-income countries still have unmet need for modern contraception. HIV and sexually transmitted infections (STIs) are global health crises, with over 1 million people contracting a new STI every day and 1.5 million people newly infected with human immunodeficiency virus (HIV) every year. Herpes simplex virus type 2 (HSV-2) is an incurable sexually transmitted infection that affects over 491 million people worldwide, 64% of whom are women. Human papillomavirus (HPV) is the most common viral infection of the reproductive tract, with most sexually active people infected at some point in their lives. New, innovative HIV and STI prevention methods and expanded contraceptive options are urgently needed to help meet these pressing and overlapping health needs.
Scientists at the Population Council Center for Biomedical Research are committed to identifying new drugs and delivery systems, conducting preclinical studies and late-stage clinical trials, and working with regulatory authorities to bring new technologies to the market. With a proven track record and seven FDA-approved products, our vision is to continue to innovate and improve reproductive health by creating new contraceptive and multi-purpose prevention technologies that expand user control, enhance safety and choice, and provide secondary benefits.
We develop our products in conjunction with the Population Council’s social and behavioral scientists all over the world. Colleagues help to ensure that the end-user perspective is incorporated into our product design throughout the development process. Our products are rigorously tested and evaluated and submitted to stringent regulatory authorities for review and approval.